公开(公告)号：WO2023075623A1

公开(公告)日：2023-05-04

申请号：PCT/PT2022/050028

申请日：2022-10-26

Applicant: INEB (INSTITUTO NACIONAL DE ENGENHARIA BIOMÉDICA) ,  UNIVERSIDADE DO PORTO

Inventor： DOS SANTOS CUNHA, Carla Marisa ,  DOS SANTOS BARBER, Susana Gomes ,  MONTEIRO DA ROCHA BARBOSA, Mário Adolfo ,  DA SILVA PEREIRA, Paulo Miguel

IPC: C12N5/0786 ,  A61P19/02 ,  A61P29/00 ,  A61K35/15 ,  A61K48/00 ,  C12N2501/052 ,  C12N2501/15 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2313 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2506/115 ,  C12N5/0645

Abstract: The present invention refers to monocytes and macrophages for use in the treatment of intravertebral disc (IVD) herniation. Furthermore, the macrophage cell phenotype which is most effective for use in a phagocytosis immunotherapy is herein disclosed. Thus, the present invention provides compositions comprising such macrophage phenotypes and a method for differentiation, polarization, and purification of the most effective macrophage phenotype, as well as its preferred form of administration. Another aspect of the present invention refers to the compositions employed in the said polarization of the most effective macrophage phenotype. Yet another aspect of the present invention refers to the compositions employed in the purification of the most effective macrophage phenotype through negative selection. The uses, compositions and methods of the present invention can be advantageously employed in a cell-based therapy primarily for use in the treatment of intervertebral disc (IVD) herniation, as well as for other clinical conditions improved by the regression of regeneration-adverse reactive tissues, such as wound and surgery- related scar tissue, fibrosis and necrosis; the said clinical condition being selected from the list further consisting of myocardial infraction, endometriosis, pulmonary asthma, hepatic cirrhosis, spinal cord injury and cartilage injury.

公开(公告)号：WO2022006020A1

公开(公告)日：2022-01-06

申请号：PCT/US2021/039464

申请日：2021-06-28

Applicant: TR1X, INC.

Inventor： RONCAROLO, Maria, Grazia ,  DE VRIES, Jan, Egbert

IPC: A61K35/17 ,  C12N5/0783 ,  A61K38/2066 ,  C12N2501/231 ,  C12N2501/505 ,  C12N2510/00 ,  C12N5/0637

Abstract: The present disclosure provides a population of poly-donor CD4IL-10 cells generated by genetically modifying CD4+ T cells from at least three different T cell donors. Further provided are methods of generating the poly-donor CD4IL-10 cells and methods of using the poly-donor CD4IL-10 cells for immune tolerization, treating GvHD, cell and organ transplantation, cancer, and other immune disorders.

公开(公告)号：WO2022005462A1

公开(公告)日：2022-01-06

申请号：PCT/US2020/040372

申请日：2020-06-30

Applicant: TR1X, INC.

Inventor： RONCAROLO, Maria, Grazia ,  DE VRIES, Jan, Egbert

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  A61K38/2066 ,  C12N2501/231 ,  C12N2501/505 ,  C12N2510/00 ,  C12N5/0637

Abstract: The present disclosure provides a population of poly-donor CD4IL-10 cells generated by genetically modifying CD4+ T cells from at least three different T cell donors. Further provided are methods of generating the poly-donor CD4IL-10 cells and methods of using the poly-donor CD4IL-10 cells for immune tolerization, treating GvHD, cancer, and other immune disorders.

公开(公告)号：WO2023288283A2

公开(公告)日：2023-01-19

申请号：PCT/US2022/073746

申请日：2022-07-14

Applicant: SYNTHEKINE, INC.

Inventor： KOCHEL, Christina ,  MURPHY, Richard B. ,  OFT, Martin ,  PENAFLOR-ASPURIA, Paul-Joseph

IPC: A61K35/17 ,  A61K38/20 ,  C07K14/705 ,  C12N5/0783 ,  A61K38/00 ,  C07K14/55 ,  C12N2501/2302 ,  C12N2501/231 ,  C12N2510/00 ,  C12N5/0636

Abstract: The present disclosures relates to methods of use to the use of interleukin-2 (IL2) muteins, pharmaceutical formulations thereof, methods useful in the treatment of human disease in combination with adoptive cell therapy. In particular, the present disclosure provides compositions and methods for the use of αβhIL2 muteins that selectively stimulate the proliferation of antigen experienced T cells ex vivo and optionally in vivo; methods of use of αβhIL2 muteins for the activation and expansion of antigen experienced T cells in an isolated population of cells; methods of use of αβhIL2 muteins ex vivo for the to prepare a population of cells enriched for antigen experienced T cells and administering the population of cells to a subject; methods of use of αβhIL2 mutein ex vivo to prepare a population of cells enriched for antigen experienced T cells and administering the population of cells to a subject and administering to said subject a therapeutically effective amount of a αβhIL2 mutein (e.g., such that the administered population of cells proliferate and have a therapeutic effect) and compositions comprising populations T cells of enriched for antigen activated cells.

公开(公告)号：WO2021237762A1

公开(公告)日：2021-12-02

申请号：PCT/CN2020/093716

申请日：2020-06-01

Applicant: 青岛瑞思德生物科技有限公司

Inventor： 张炳强 ,  陈梦梦

IPC: C12N5/0775 ,  A61K35/28 ,  C12N5/00 ,  A01N1/0221 ,  C12N2500/90 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/21 ,  C12N2501/231 ,  C12N2501/235 ,  C12N2501/39 ,  C12N2501/405 ,  C12N2501/999 ,  C12N5/0605 ,  C12N5/0663 ,  C12N5/0665 ,  C12N5/0668 ,  C40B50/06

Abstract: 本发明公开了一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法。该方法包括：利用间充质干细胞专用原代筛选培养基进行第一阶段筛选培养，得到纯化的间充质干细胞；利用间充质干细胞专用激活扩增培养基将纯化的间充质干细胞进行第二阶段激活和大规模扩增培养，获得大量激活功能的间充质干细胞；利用间充质干细胞专用冻存液冻存干细胞，并按ABO/RH分型和HLA分型进行保存，建立可供检索的信息档案，构建间充质干细胞库。

公开(公告)号：WO2021123255A1

公开(公告)日：2021-06-24

申请号：PCT/EP2020/087151

申请日：2020-12-18

Applicant: CORDES BIOTECH A/S

Inventor： CORDES, Ulrik ,  FRIESE, Christina ,  KIRKETERP-MØLLER, Nikolaj ,  HEEKE, Christina

IPC: C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  A61P31/12 ,  C07K14/47 ,  C07K14/705 ,  C07K14/715 ,  C07K16/2809 ,  C07K2317/70 ,  C12N2501/2302 ,  C12N2501/231 ,  C12N2501/2315 ,  C12N2501/24 ,  C12N2501/515 ,  C12N2502/11 ,  C12N2502/1121 ,  C12N2502/30 ,  C12N5/0638

Abstract: The present invention is targeted towards reinvigorating exhausted Tumor Infiltrating Lymphocytes (TILs) in vitro by co-culturing excised TIL containing tumor fragments with checkpoint inhibitors, stimulating the TILs with other interleukins known to revert T cell exhaustion), and/or inhibiting the effect of regulatory T cells secreted factors (such as IL-10) thereby creating a favorable tumor microenvironment (TME) where exhausted T-cells can expand faster and to higher numbers than currently established TIL expansion protocols.